Synaptogenix, Inc. (SNPX)

NASDAQ: SNPX · IEX Real-Time Price · USD
8.49
-0.09 (-1.05%)
At close: Aug 18, 2022 3:59 PM
8.50
+0.01 (0.12%)
After-hours: Aug 18, 2022 4:00 PM EDT
-1.05%
Market Cap 58.08M
Revenue (ttm) n/a
Net Income (ttm) -14.19M
Shares Out 6.84M
EPS (ttm) -2.12
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 38,942
Open 8.58
Previous Close 8.58
Day's Range 8.36 - 8.63
52-Week Range 3.79 - 14.50
Beta n/a
Analysts Buy
Price Target 14.28 (+68.2%)
Earnings Date Aug 12, 2022

About SNPX

Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Ic... [Read more...]

Industry Biotechnology
Founded 2012
Employees 4
Stock Exchange NASDAQ
Ticker Symbol SNPX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for SNPX stock is "Buy." The 12-month stock price forecast is 14.28, which is an increase of 68.20% from the latest price.

Price Target
$14.28
(68.20% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Synaptogenix Announces Live Appearance of its President and CSO on Streaming Financial News Network

NEW YORK , Aug. 12, 2022 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("the Company"), a clinical-stage biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorder...

Synaptogenix Announces Changes to Scientific Advisory Board in Preparation for Phase 2 Data

Conference Call to be held Tuesday, July 26th at 4:30pm ET NEW YORK , July 26, 2022 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("the Company"), a clinical-stage biopharmaceutical company developi...

Synaptogenix Announces Corporate Update Conference Call

NEW YORK , July 21, 2022 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("the Company"), a clinical-stage biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorder...

Synaptogenix Advances Dosing of First Patient in Dose Optimization Clinical Trial in Preparation for NIH-Sponsored, P...

Dose optimization prepares the Company for its next phase of Bryostatin clinical development Company expects to announce topline data from its NIH sponsored Phase 2 clinical study during the fourth quar...

Synaptogenix to Present at the Cell Symposium

NEW YORK , May 17, 2022 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing regenerative therapeutics for neurodegenerat...

Synaptogenix Completes Patient Enrollment in NIH Sponsored Phase 2b Alzheimer's Disease Trial

- Top line results expected during the fourth quarter of 2022 - Data Safety Monitoring Board has confirmed no adverse safety issues NEW YORK , April 19, 2022 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: ...

New Peer Reviewed Article Demonstrates Extended Therapeutic Potential of Synaptogenix's Bryostatin for Alzheimer's Di...

Treatment with Bryostatin shown to increase blood vessel health, a key factor for prevention and disease reversal National Institutes of Health (NIH)-sponsored Phase 2b clinical trial of Bryostatin-1 in...

Synaptogenix to Present at Hanson Wade 10th Annual Neurodegenerative Drug Development Summit

NEW YORK , March 29, 2022 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing regenerative therapeutics for neurodegener...

Synaptogenix to Present at Sachs 5th Annual Neuroscience Innovation Forum

NEW YORK , March 22, 2022 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing regenerative therapeutics for neurodegener...

Synaptogenix to Present Research Highlighting Potential Broad Applicability for Lead Compound Bryostatin at the Inter...

NEW YORK , March 15, 2022 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX), an emerging biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, announced today t...

Synaptogenix Moves Forward with Clinical Development Plans for Bryostatin-1 as a Treatment for Multiple Sclerosis

NEW YORK, Feb. 23, 2022 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX), a clinical-stage biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, today announce...

Synaptogenix Announces Publication of Peer-Reviewed Scientific Article Evidencing Byrostatin-1's Improved Cognition O...

NEW YORK, Feb. 1, 2022 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("the Company"), a clinical-stage biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders,...

5 Short Squeeze Candidates To Watch: Huadi Tops List, Altimeter Group And Bit Digital Rejoin Leaderboard

Potential short squeeze plays have gained steam in 2021 with new retail traders looking for the next GameStop Corp (NYSE:GME) or AMC Entertainment Holdings Inc (NYSE:AMC). A short squeeze can occur when...

Other symbols: BTBTHUDI

Rebuilding Connections, Fostering Growth: Synaptogenix Could Be A Beacon of Hope for Patients With Neurological Diseases

Image by Gerd Altmann from Pixabay  How well we think, feel and act rests in the hands of trillions of tiny connectors in our minds.

Synaptogenix Announces Participation at the H.C. Wainwright 23rd Annual Global Investment Conference

NEW YORK, Sept. 10, 2021 /PRNewswire/ -- Synaptogenix, Inc (Nasdaq: SNPX), an emerging biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, today announced it ...

Synaptogenix Signs Memorandum Of Understanding with Nemours A.I. DuPont Hospital to Initiate Trial Using Bryostatin, ...

NEW YORK, Aug. 5, 2021 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX), an emerging biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, today announced that...

Synaptogenix Stock Drops After Unveiling Analyses Of Alzheimer's Candidate

Synaptogenix Inc (NASDAQ: SNPX) stock is plunging on heavy volume in reaction to the release of additional analyses of its Alzheimer's candidate bryostatin, showing that it missed primary endpoints. The...

Synaptogenix Discloses Positive Results of Further Bryostatin Trial Analyses in Presentation at Alzheimer's Associati...

NEW YORK, July 26, 2021 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced that its ...

Synaptogenix Announces Conference Call to Discuss AAIC Abstract Findings

NEW YORK, July 21, 2021 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced that it w...

Synaptogenix to Present Data at Alzheimer's Association International Conference 2021 Highlighting Bryostatin Restore...

NEW YORK, July 14, 2021 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced that its ...

Synaptogenix Announces Regenerative Patent Award to Treat Alzheimer's Disease

NEW YORK, July 7, 2021 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced that a new...

Synaptogenix Announces $12.5 Million Private Placement

NEW YORK, June 14, 2021 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced that it h...

Synaptogenix's Alzheimer's Candidate Displays Signs Of Safety In Mid-Stage Study

Synaptogenix Inc (NASDAQ: SNPX) has announced an update on its ongoing National Institutes of Health (NIH) sponsored Phase 2b trial of Bryostatin-1 for moderately severe Alzheimer's disease (AD). To dat...

Synaptogenix Announces Phase 2b NIH Sponsored Alzheimer's Disease Trial Update

NEW YORK, June 9, 2021 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced an update ...

Synaptogenix Responds to FDA Approval of Aducanumab

NEW YORK, June 7, 2021 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today issued a statement f...